The purpose of this study is to evaluate the study drug, DS-8201a (also known as Enhertu or fam-trastuzumab deruxtecan-nxki) for advanced solid tumors. The study aims to see how DS-8201a affects the levels of certain proteins and immune cells in solid tumors, how well it works against cancer cells, and how safe and tolerable it is.
The United States Food and Drug Administration (FDA) has approved DS-8201a for the treatment of patients with advanced HER2-positive breast or gastric cancer.
Participants will receive DS-8201a intravenously every three weeks. Cells will be examined from a small piece of the tumor taken before DS-8201a is given and after DS-8201a is given. Participants will continue to receive DS-8201a as long as their cancer does not worsen, side effects are tolerable, and they agree to stay in the study.
Detailed eligibility will be reviewed when you contact the study team.